CervoMed Inc. - 8-K Filing
CervoMed reported Q1 2026 financial results with $12.9 million cash as of March 31, down from $20.9 million in December 2025, and a net loss of $8.0 million for the quarter compared to $4.9 million in the same period last year due to lower grant revenue and higher R&D expenses. The company anticipates its cash runway will extend into September 2026 based on current operating plans. (Items: 2.02 Results of Operations and Financial Condition On May 18, 2026, CervoMed Inc, 7.01 Regulation FD Disclosure Anticipated Cash Runway As previously announced, as of March 31, 2026, we had approximately $12, 9.01 Financial Statements and Exhibits (d) Exhibits Exhibit No)
Tickers: $CRVO